Cargando…
Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial
BACKGROUND: Modified Vaccinia Ankara (MVA) is a live, viral vaccine under advanced development as a non-replicating smallpox vaccine. A randomised, double-blind, placebo-controlled phase III clinical trial was conducted to demonstrate the humoral immunogenic equivalence of three consecutively manufa...
Autores principales: | Overton, Edgar Turner, Lawrence, Steven J., Wagner, Eva, Nopora, Katrin, Rösch, Siegfried, Young, Philip, Schmidt, Darja, Kreusel, Christian, De Carli, Sonja, Meyer, Thomas P., Weidenthaler, Heinz, Samy, Nathaly, Chaplin, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898760/ https://www.ncbi.nlm.nih.gov/pubmed/29652929 http://dx.doi.org/10.1371/journal.pone.0195897 |
Ejemplares similares
-
A randomized phase 3 trial to assess the immunogenicity and safety of 3 consecutively produced lots of freeze-dried MVA-BN® vaccine in healthy adults
por: Turner Overton, Edgar, et al.
Publicado: (2023) -
LB11. A Single Dose of the MVA-BN Smallpox Vaccine Induces an Early Protective Antibody Response Similar to a Traditional Replicating Vaccine and Is Suitable for Emergency Scenarios
por: Maclennan, Jane, et al.
Publicado: (2019) -
A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis
por: Greenberg, Richard N, et al.
Publicado: (2015) -
One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines
por: Ilchmann, Heiko, et al.
Publicado: (2022) -
Correction: A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis
por: Greenberg, Richard N, et al.
Publicado: (2015)